Eli Lilly and Company announced that its Phase III SEQUOIA trial of pegilodecakin plus FOLOFX (folinic acid, 5-FU, oxaliplatin) in metastastic pancreatic cancer that had progressed during or after first-line gemcitabine-containing regimen did not meet its primary endpoint.
Mylan and Hospira are both recalling injected medications because potentially dangerous particulate has been discovered in them. Mylan is recalling a chemotherapy drug, while Hospira is recalling a solution often used to treat diabetes.
Mylan Institutional LLC is conducting a voluntary nationwide recall of two lots (see table below) of Levoleucovorin Injection, 250 mg/25 mL to the consumer/user level. The lots were manufactured by Alidac Pharmaceuticals Limited and distributed by Mylan Institutional LLC. The Levoleucovorin Injection is being recalled due to the presence of particulate matter identified as copper salts. The particulate matter was discovered during 12-month stability testing.
Alnylam Pharmaceuticals has entered an agreement with Medison Pharma to commercialise its RNAi therapeutic Onpattro in Israel. Novartis has signed an agreement to use Kinaxis’ RapidResponse platform, a Cloud-based software that provides country-specific product expiry monitoring and planning across a company’s global network.
Amneal Pharm’s Generic Levoleucovorin Receives Tentative Approval In US
The drug was cleared for use in Europe to treat metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil (5-FU) and leucovorin (LV), in adult patients who have progressed following gemcitabine-based therapy
Market Place
Share Share
Share Share
